Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.11851/1399
Title: Nerve-glial antigen 2: A novel target for anti-tumor therapy in colorectal cancer
Authors: Cengiz, Cem
Bulut, Şafak
Boyacıoğlu, A. Sedat
Kuzu, M. Ayhan
219000
Keywords: Nerve/glial antigen 2
Colorectal cancer
Angiogenesis inhibitors
Targeted tumor therapy
Issue Date: Aug-2017
Publisher: Karger
Source: Cengiz, C., Bulut, S., Boyacioglu, A. S., & Kuzu, M. A. (2017). Nerve/Glial antigen 2: A novel target for anti-tumor therapy in colorectal cancer. Digestion, 96(1), 60-66. doi:10.1159/000478853
Abstract: Background/Aims: To identify cell surface markers selectively expressed by tumor cells and tumor vasculature is the current goal for tumor therapy. One such marker is nerve/glial antigen 2 (NG2), which is a transmembrane glycoprotein. We aimed to investigate the expression of NG2 in colorectal cancer (CRC) and its association with clinicopathological parameters. Methods: Immunohistochemical staining of NG2, vascular endothelial growth factor, and CD34 in 65 patients diagnosed with CRC over a 5-year period was performed. NG2 expression in both tumor cells and tumor vasculature was scored according to the German Reactive Scoring System. The association between NG2 and patient and tumor characteristics was analyzed. Results: NG2 was expressed by tumor cells in 56.9%, tumor vasculature in 43%, and simultaneously by both in 27.6% of the cases. Tumor cell NG2 was more common in elderly patients (p = 0.023) and vascular NG2 was associated with better tumor differentiation (p = 0.035). Notably, vascular NG2 was expressed in half of the patients with left colon cancer, although it was not expressed in a majority of those with right colon cancer (50.9 vs. 17.7%, p = 0.041). Conclusion: Both tumor cell and vascular NG2 expression were shown to be present in a significant number of patients with CRC and this makes NG2 a double target for anti-tumor therapies. Such therapies might be more effective for elderly patients with well-differentiated left colon cancer. © 2017 S. Karger AG, Basel.
URI: https://www.karger.com/Article/FullText/478853
https://hdl.handle.net/20.500.11851/1399
ISSN: 0012-2823
Appears in Collections:Dahili Tıp Bilimleri Bölümü / Department of Internal Medical Sciences
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record

CORE Recommender

WEB OF SCIENCETM
Citations

1
checked on Sep 24, 2022

Page view(s)

22
checked on Dec 26, 2022

Google ScholarTM

Check

Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.